Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - mefloquine hydrochloride, quantity: 274.09 mg (equivalent: mefloquine, qty 250 mg) - tablet, uncoated - excipient ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer - malaria treatment: lariam is indicated for the treatment of acute attacks of malaria due to p.falciparum infection resistant to conventional antimalarial drugs. following therapy of mixed p.falciparum/p.vivax malaria with lariam relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of p.vivax. malaria prophylaxis: for travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant p.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). for travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant p.fal

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - ambrisentan viatris is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension (pah),,- pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - ambrisentan viatris is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension (pah),,- pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

Singapor - Ingliż - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - (15mg tablet) tolvaptan; (45mg tablet) tolvaptan - tablet - (15mg tablet) tolvaptan 15.000mg; (45mg tablet) tolvaptan 45.0mg

Singapor - Ingliż - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - (30mg tablet) tolvaptan; (60mg tablet) tolvaptan - tablet - (30mg tablet) tolvaptan 30.000mg; (60mg tablet) tolvaptan 60.000mg

Singapor - Ingliż - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - (30mg tablet) tolvaptan; (90mg tablet) tolvaptan - tablet - (30mg tablet) tolvaptan 30.000mg; (90mg tablet) tolvaptan 90.0mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

osmotica pharmaceutical corp. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - tablet, extended release - 37.5 mg - venlafaxine extended release tablets (venlafaxine hydrochloride) are indicated for the treatment of major depressive disorder (mdd). efficacy of venlafaxine in mdd was shown in both short-term trials and a longer-term trial in mdd [see clinical studies (14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. venlafaxine extended release tablets are indicated for the treatment of social an

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; calcium phosphate; purified talc; lactose monohydrate; wheat starch; gelatin - treatment of attention-deficit hyperactivity disorder (adhd). treatment of narcolepsy.

Tanżanija - Ingliż - Tanzania Medicinces & Medical Devices Authority

resonant pharmaceuticals pvt. ltd., india - metformin , glimepiride - tablets - 500/2